Drug intelligence / Profile preview

FH-006

Development stage: Phase 3
Lead developer: Hengrui Pharmaceutical
Administration: Intravenous

Overview

FH-006 is an investigational biological product being developed as an injectable therapy for the treatment of advanced malignant solid tumors. It is currently undergoing Phase I/II clinical trials to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors. The drug is administered intravenously every two weeks in a 28-day treatment cycle. While the precise mechanism of action has not been publicly disclosed, it is classified as a biological product new drug and intended for oncology indications. The development involves collaboration between Fuhong Biopharma (Shanghai Fuhong Biopharmaceutical) and Jiangsu Hengrui Pharmaceuticals.

Beyond the preview

Go deeper on FH-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FH-006.

Explore the full profile